IA
RVNC

IFP Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

IFP Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– – – 4047
2024
Q4 		– Hold
0
– – – 4340
2023
Q4 		– Sell
-75
Closed -$860 – 3387
2023
Q3 		$860 Hold
75
– – ﹤0.01% 3030
2023
Q2 		$1.9K Sell
75
-2,000
-96% -$62.3K ﹤0.01% 2897
2023
Q1 		$59.6K Buy
2,075
+2,000
+2,667% +$62.3K ﹤0.01% 1491
2022
Q4 		$2K Sell
75
-9
-11% -$206 ﹤0.01% 4246
2022
Q3 		$3K Hold
84
– – ﹤0.01% 4282
2022
Q2 		$3K Hold
84
– – ﹤0.01% 4048
2022
Q1 		$3K Buy
84
+9
+12% +$136 ﹤0.01% 4048
2021
Q4 		$1K Buy
+75
New +$1.25K ﹤0.01% 3159
2017
Q3 		– Sell
-1,250
Closed -$33K – 4240
2017
Q2 		$33K Buy
1,250
+250
+25% +$5.58K ﹤0.01% 2260
2017
Q1 		$21K Buy
+1,000
New +$20.5K ﹤0.01% 2487
2016
Q1 		– Sell
-7
Closed – – 3524
2015
Q4 		$0 Buy
+7
New +$243 ﹤0.01% 3807

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors's RVNC Position: Q1 2025 in Review

IFP Advisors held its Revance Therapeutics, Inc. (RVNC) position steady in Q1 2025 at 0 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #4047.

IFP Advisors first reported a position in RVNC in Q4 2015 and has held it in 11 quarters since. The position peaked at $59.6K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • IFP Advisors held 0 shares of Revance Therapeutics, Inc. worth $44 as of Q1 2025.
  • IFP Advisors left its Revance Therapeutics, Inc. share count unchanged in Q1 2025.
  • Revance Therapeutics, Inc. made up ﹤0.01% of IFP Advisors's portfolio in Q1 2025, its #4047 holding.
  • IFP Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2015 and has held it in 11 quarters since.
  • IFP Advisors's Revance Therapeutics, Inc. position peaked at $59.6K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on IFP Advisors's 13F filing for Q1 2025, filed 5 May 2025.